NWRN (NWRN) News
Follow NWRN (NWRN) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 8 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
US FDA cites four deaths behind Newron schizophrenia trial hold
Newron Pharmaceuticals said the US FDA outlined safety concerns behind a clinical hold at US sites in a late-stage schizophrenia-drug trial, citing four deaths and irregular heart rhythms.
REGULATION | Oct 08, 2026, 12:26 PM UTC
L
Newron Pharmaceuticals S.p.A. (NWRN) FDA U.S. Hold on ENIGMA-TRS 2 Enrollment Remains
Newron said the FDA will keep the U.S. enrollment hold for Phase 3 ENIGMA-TRS 2 after an external sudden death report; enrollment continues ex-U.S. with site expansion. Topline ENIGMA-TRS 1 12-week data are expected in Q
REGULATION | Sep 25, 2026, 03:49 PM UTC
L
Newron Provides Update on Phase 3 ENIGMA-TRS 2 Study
Ad hoc announcement pursuant to Art. 53 LRU.S. clinical hold remains in place; study continues in all other countriesCompany initiates expansion of clinical sites and enrollment in Europe, Asia and Latin AmericaTopline d
NEWS | Sep 25, 2026, 03:49 PM UTC
L
Newron Says Topline Data From ENIGMA-TRS 1 Expected In Q1 2027
Newron Pharmaceuticals SpA BX:NWRN
NEWS | Sep 25, 2026, 03:47 PM UTC
M
Newron reports H1 2026 results; ENIGMA-TRS 1 nears target
Newron said ENIGMA-TRS 1 is nearing its ≥600-patient target (996 screened) and topline 12-week data are expected in Q1 2027. It also said U.S. enrollment in ENIGMA-TRS 2 is expected to resume after FDA clearance.
EARNINGS | Sep 22, 2026, 11:03 AM UTC
M
Newron subscription for EUR 5.5M shares under up to EUR 38M financing
Newron said an investor group subscribed for shares worth EUR 5.5 million as part of total financing of up to EUR 38 million. Proceeds are expected to fund ENIGMA-TRS studies and extend cash runway beyond 12-week results
EQUITY | Sep 08, 2026, 11:08 AM UTC
L
Newron Pharmaceuticals to take part in H.C. Wainwright 28th conference
Newron Pharmaceuticals S.p.A. said it will participate in the H.C. Wainwright 28th Annual Global Investment Conference.
EQUITY | Sep 03, 2026, 11:08 AM UTC
L
Newron completes screening for ENIGMA-TRS 1 Phase 3 enrollment
Newron Pharmaceuticals said it has completed screening for enrollment in its pivotal Phase 3 ENIGMA-TRS 1 study. Evenamide will be used as add-on therapy in patients with treatment-resistant schizophrenia.
EQUITY | Sep 02, 2026, 05:02 AM UTC